Department of Surgery
Andrew N. De la Torre, M.D.
Clinical InfoMedical Expertise
1) Liver, Pancreas & Bile duct Surgery (Minimal access, Laparoscopic & open) 2) Clinical trials in cancers of the liver and pancreas.
University Hospital, Newark
St. Michael's Medical Center - Newark
Insurance Participation: with Provider Number ( where applicable ) The information below is subject to change and should not be relied upon until after it is verified with the insurance company. In addition, psychiatric providers should be contacted directly for information on their participation with managed care and insurance companies.
- Aetna, Inc.
- Devon Health Services/ULLICO
- FedMed, Inc
- Horizon BCBS Managed Care
- Horizon NJ Health
- Oxford Health Plans
- Prime Health Services, Inc.
- Qual Care HMO
- Qual Care PPO
- Three Rivers Provider Network
- United Health Care Corp
- United Healthcare Community Plan (formerly AmeriChoice of NJ, Inc.)
Post Transplant Administration of Vitamin D3 to Induce Toleragenic Dendritic Cell Function, Assessment of Vitamin D3 Safety
Immunomodulation of Human Hepatocellular Carcinoma by Interferon Lambda: Increasing Hepatocellular Carcinoma as a Target of Anti-tumor Immuno-responsiveness
A Phase Ib Randomized, Placebo-controoled Clinical Trial to Study and Efficacy of MK-7009 in Hepatitis C Infected Patients
Autologous anti-tumor vaccination: Use of 3-dimensional conformal irradiation and intra/peri-tumoral injection of polyinosinic-polycytidylic acid polylysine (Pol-ICLC, Hiltonol®) followed by hepatic trans-arterial embolization (TAE), a strategy to build robust cytotoxic immunity against primary and metastatic malignancies of the liver.
To study the safety and effectiveness of a strategy to establish robust anticancer immunologic body defenses by using low-dose radiation therapy to the liver cancer in order to increase tumor target ability; inject a body defense activator, polyinosinic-polycytidylic acid polylysine carboxymethylcellulose (poly ICLC, hiltonol, oncovir), into and around the cancer to activate sentinel dendritic cells to alarm body defenses; and shut down local production of factors that suppress the body's natural anticancer defenses by starving the cancer of its blood supply within the liver.
A Phase 1 Study to Assess the Safety and Antiviral Activity of PEG-rIL-29 Administered as a Single Agent and in Combination with Ribavirin in Subjects with Treatment-Relapsed Chronic Hepatitis C Virus Infection
This is a 2-part study of PEG-rIL-29 in subjects with chronic genotype 1 hepatitis C virus infection who have relapsed following prior treatment with a PEGylated IFN-± (or other form of IFN-±) and ribavirin. Part 1 of the study will evaluate the safety and tolerability of escalating doses of PEG-rIL-29 when given as a single agent either every other week or weekly over a 4-week period. Part 2 of the study will evaluate dose levels and/or schedules of PEG-rIL-29 selected from Part 1 in combination with daily oral ribavirin administered over a 4-week period.
Use of Audio-CASI to Understand obstacles to the Diagnosis of Chronic Viral Hepatitis
Use of audio-computer assisted survey interview to identify patients in need of hepatitis B and C blood testing, non-alcoholic fatty liver disease, and liver cancer.
Johns Hopkins School of Medicine
Class of 1989
Queens College, CUNY
Flushing, New York
Class of 1984
New Jersey Medical School
Newark, New Jersey
Kidney and Pancreas transplant
University of Maryland Medical Systems
New Jersey Medical School
Newark, New Jersey
M.D., 1989, Johns Hopkins University School of Medicine
Licensure & Certification
|Muir AJ, Shiffman ML, Zaman A, Yoffe B, de la Torre A, Flamm S, Gordon S, Marotta P, Vierling J, Lopez-Talavera JC, Byrnes-Blake K, Fontana D, Freeman J, Gray T, Hausman D, Hunder NN, Lawitz E. Phase 1b Dose-Ranging Study of PEG- Interferon-Lambda Plus Ribavirin in Patients with Chronic Genotype 1 Hepatitis C Virus Infection. Hepatology. 2010 May 14|
|Abushahba W, Lasfar A , Balan M, Castaneda I, Yuan Y, Prescott L, Reuhl K, Raveche E, de la Torre AN, Kotenko SV. Antitumor Activity of Type I and Type III Interferons in BNL Hepatoma Model. Cancer Immunol Immunother. 2010 Mar 9|
|Ferrante JM, Winston DG, Chen PH, de la Torre AD Family Physicians’ Knowledge and Practices Regarding Chronic Hepatitis and Monitoring for Liver Cancer. Family Medicine Family Medicine 2008 May: 40(5), 345-351|
|Koneru B, Shareef A, Dikdan G, Desai K, Klein KM, Peng B, Wachsberg RH, de la Torre AN, Debroy M, Fisher A, Wilson DJ, Samanta AK. The ischemic preconditioningparadox in deceased donor liver transplantation-evidence from a prospectiverandomized single blind clinical trial. Am J Transplant. 2007 Dec;7(12):2788-96.|
|Abujudeh H, Contractor D, delaTorre A, Koneru B. Rescue TIPS in acute Budd-Chiari syndrome. AJR Am J Roentgenol. 2005 Jul;185(1):89-91|
|Ponnudurai RN, Koneru B, Akhtar SA, Wachsberg RH, Fisher A, Wilson DJ, de la Torre AN. Vasopressor administration during liver transplant surgery and its effect on endotracheal reintubation rate in the postoperative period: a prospective, randomized, double-blind, placebo-controlled trial. Clin Ther. 2005 Feb;27(2):192-8|
|Koneru B, Fisher A, He Y, Klein KM, Skurnick J, Wilson DJ, de la Torre AN, Merchant A, Arora R, Samanta AK. Ischemic preconditioning in deceased donor liver transplantation: a prospective randomized clinical trial of safety and efficacy. Liver Transpl. 2005 Feb;11(2):196-202|
|Harrison LE, Reichman T, Koneru B, Fisher A, Wilson D, dela Torre A, Samanta A, Korogodsky M. Racial discrepancies in the outcome of patients with hepatocellular carcinoma. Arch Surg. 2004 Sep;139(9):992-6|
|Fisher A, Seguel JM, de la Torre AN, Wilson D, Merchant A, Arora RK, Koneru B. Effect of sirolimus on infection incidence in liver transplant recipients. Liver Transpl. 2004 Feb;10(2):193-8|
|16. Harrison LE, Koneru B, Baramipour P, Fisher A, Barone A, Wilson D, dela Torre AN, Cho KC, Contractor D, Korogodsky M. Locoregional recurrences are frequent after radiofrequency ablation for Hepatocellular carcinoma. J Am Coll Surg J Am Coll Surg. 2003 Nov; 197(5): 759-64|
Areas of Interest
Immunotherapy Against Cancers in the Liver
My work focuses on immune stimulation to fight primary and metastatic cancers in the liver. There are 2 main protocols. The first (clinicaltrials.gov Protocol ID NCT00553683) uses autologous prime-boost anti-tumor vaccination in patients with hepatomas or metastatic cancers (pancreas, neuroendocrine, gastric, colon, breast) to the cancer in the liver. This is a phase I/IIa clinical trial using 1) low dose cyclophosphamide to reduce tumor driven immune tolerance, 2) low dose radiation to the tumor, to increase expression of tumor antigens, 3) injection of an immune stimulant, TLR III agonist Poly IC:LC, into and around the tumor to activate the body’s immune defenses, and 4) tumor ablation to reduce production of tumor promoting and immunosuppressive factors. This is referred to as “Priming”. Patients are then subject to systemic administration of POLY ICLC to “Boost” the anti-tumor immune response. The second (clinicaltrials.gov Protocol ID NCT01387555) uses an oncolytic poxvirus, or vaccinia virus (JX-594) that are highly selective to attack cancers and have minimal side effects, limited to flu-like symptoms. The (JX-594 strain backbone of has been used safely in millions of people as part of a worldwide vaccination program. Features include 1) rapid and motile spread in tumors (increased potency), 2) intravenous stability and delivery to solid tumors, 3) therapeutic transgene-arming capacity, and 4) antidotes are available (to maximize safety). JX-594 is an engineered oncolytic virus designed to selectively destroy cancer cells through three diverse mechanisms of action: 1) the lysis of cancer cells through viral replication, 2) the reduction of the blood supply to tumors through vascular targeting and destruction, and 3) the stimulation of the body's immune response against cancer cells. JX-594 exploits a specific genetic feature in cancer cells to become activated and lyse the cells, including the EGFR-ras signaling pathway, the cell cycle activation and the loss of cellular interferon defenses. JX-594 is a Wyeth vaccinia virus with a disruption of the viral thymidine kinase (tk) gene and expression of the immunostimulatory cytokine, GM-CSF (granulocyte macrophage colony-stimulating factor).